[1]王 辉,袁 捷,韩祖成,等.基于平衡TF/TFPI水平研究三七在心房颤动大鼠治疗中维持抗凝/出血稳态的作用及机制[J].陕西中医,2021,(11):1522-1526.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.006]
　WANG Hui,YUAN Jie,HAN Zucheng,et al.Effect and mechanism of Panax notoginseng on maintaining anticoagulation/bleeding homeostasis in rats with atrial fibrillation based on balanced TF/TFPI levels[J].,2021,(11):1522-1526.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.006]
点击复制

基于平衡TF/TFPI水平研究三七在心房颤动大鼠治疗中维持抗凝/出血稳态的作用及机制
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年11期
页码:
1522-1526
栏目:
基础研究
出版日期:
2021-11-05

文章信息/Info

Title:
Effect and mechanism of Panax notoginseng on maintaining anticoagulation/bleeding homeostasis in rats with atrial fibrillation based on balanced TF/TFPI levels
作者:
王 辉1; 2; 袁 捷3; 韩祖成3; 刘冬玲3; 陈 杰3; RASSUL4(哈萨克斯坦)
(1.天津中医药大学,天津 301617; 2.西安市中医医院,陕西 西安 710021; 3.陕西省中医医院,陕西 西安 710003; 4.陕西中医药大学,陕西 咸阳 712046)
Author(s):
WANG Hui; YUAN Jie; HAN Zucheng; LIU Dongling; CHEN Jie; RASSUL
(Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China)
关键词:
心房颤动;  三七;  抗凝/出血;  组织因子;  组织因子途径抑制物
Keywords:
Atrial fibrillation;  Panax notoginseng;  Anticoagulation/bleeding;  Tissue factor;  Tissue factor pathway inhibitors
分类号:
R 541.75
DOI:
DOI:10.3969/j.issn.1000-7369.2020.11.006
文献标志码:
A
摘要:
的:从平衡组织因子(TF)、组织因子途径抑制物(TFPI)水平角度,研究三七对心房颤动(AF)大鼠眼眦静脉血液TF、TFPI表达水平、血凝系列、抗凝/出血风险的影响,来探讨三七维持抗凝/出血稳态的可能作用机制,为中药抗凝治疗提供理论依据。 方法:以新鲜配置ACh-CaCl2混合液为造模药物,采用尾静脉注射ACh-CaCl2混合液建立房颤大鼠模型。将24只大鼠随机分为假手术组、模型组、三七组和华法林组,每组6只。各组给予相应的干预措施。通过M6240C型多道生理信号采集处理系统描记标准Ⅱ导联心电图全程记录,选取心电图典型AF表现的大鼠纳入模型及给药组,直到实验结束。采用酶联免疫吸附法(ELISA)测定血浆 TF、TFPI水平,即时检测技术(POCT)测定血凝系列。 结果:①治疗第3天,与假手术组比较,其他各组TF、TFPI值均明显升高(P<0.05); 华法林组、三七组与模型组相比TF、TFPI均有统计学差异(P<0.05),而华法林组与三七组相比无统计学差异(P>0.05); ②治疗第7天,与假手术组比较,其他各组TF、TFPI值均明显升高(P<0.05); 华法林组、三七组与模型组相比TF、TFPI均有统计学差异(P<0.05); 华法林组与三七组相比TF水平无统计学差异(P>0.05),而TFPI有统计学差异(P<0.05); ③治疗第3天,与假手术组比较,其他各组INR值、PT均明显降低(P<0.05); 模型组、华法林组和三七组相比INR值、PT无统计学差异(P>0.05); ④治疗第7天,与假手术组比较,其他各组INR值、PT均有统计学差异(P<0.05); 华法林组、三七组与模型组对比INR值均有统计学差异(P<0.05),华法林组与三七组对比INR值、PT有统计学差异(P<0.05); ⑤假手术组、模型组、三七组大鼠在建模及治疗期间均未出现皮下出血情况; 华法林组大鼠在治疗第7天出现1只大鼠皮下瘀点。 结论:三七能通过平衡心房颤动大鼠血浆中的TF、TFPI水平,抑制高凝状态,减少血栓栓塞并发症和防止出血,从而维持抗凝/出血的稳态。
Abstract:
Objective:To investigate the effects of Panax notoginseng on Tissue factor(TF)and Tissue factor pathway inhibitors(TFPI)expression levels,hemagglutination series,and the risk of anticoagulation/bleeding in eye canthus veins of rats with atrial fibrillation,from the perspective of balancing TF and TFPI levels,to explore the possible mechanism of panax notoginseng in maintaining anticoagulation/bleeding homeostasis,and to provide theoretical basis for traditional Chinese medicine anticoagulation therapy.Methods:Fresh ACh-CaCl2 mixture was used as the modeling drug,and the rat model of atrial fibrillation was established by injecting ACh-CaCl2 mixture into tail vein.Twenty-four rats were randomly divided into sham operation group,model group,panax notoginseng group and Warfarin group,with 6 rats in each group.Each group was given corresponding intervention measures.Through type M6240C multi-channel physiological signal acquisition processing system of eeg,standard Ⅱ lead electrocardiogram(ecg)records all the way,the selection of typical AF ecg manifestation rats into the model and give medicine group,until the end of the experiment.The plasma TF and TFPI levels were determined by ELISA and the hemagglutination series were determined by POCT.Results:①On the third day of treatment,the TF and TFPI values of other groups were significantly higher than those of the sham group(P<0.05).There were statistically significant differences in TF and TFPI between the warfarin group and panax notoginseng group compared with the model group(P<0.05),while there were no statistically significant differences between the warfarin group and panax notoginseng group(P>0.05).②On the 7th day of treatment,the TF and TFPI values of other groups were significantly increased compared with the sham group(P<0.05).There were statistically significant differences in TF and TFPI between the Warfarin group and panax notoginseng group and the model group(P<0.05).Compared with panax notoginseng group,there was no significant difference in TF level between warfarin group and panax notoginseng group(P>0.05),while TFPI was significantly different(P<0.05).③On the third day of treatment,INR values and PT in all groups were significantly lower than those in the sham group(P<0.05).There was no statistical difference in INR value and PT between model group,warfarin group and panax notoginseng group(P>0.05).④On the 7th day of treatment,there were statistically significant differences in INR values and PT between the sham operation group and other groups(P<0.05).There were statistically significant differences in INR values and PT between the Warfarin group,panax notoginseng group and the model group(P<0.05),while there were statistically significant differences in INR values and PT between the Warfarin group and the panax notoginseng group(P<0.05).⑤No subcutaneous bleeding occurred in sham operation group,model group and panax notoginseng group during modeling and treatment.On the 7th day of treatment,1 rat of warfarin group presented subcutaneous petechiae.Conclusion:Panax notoginseng can maintain anticoagulation/bleeding homeostasis by balancing TF and TFPI levels in plasma of atrial fibrillation rats,inhibiting hypercoagulability,reducing thromboembolism complications and preventing bleeding.

参考文献/References:

[1] 马长生.关于心房颤动临床研究的思考[J].中华心血管病杂志,2019,47(12):935-936.
[2] 刘韦卓,周 鹏,吴帮卫,等.心房颤动综合管理平台对6923例患者随访及抗凝治疗的影响[J].中华心律失常学杂志,2020,24(3):293-297.
[3] Shahid F,Shantsila E,Lip GYH.Recent advances in the understanding and management of atrial fibrillation:A focus on stroke prevention[J].F1000Research,2016(5):2887.
[4] Alcocer L.Challenges and treatment for stroke prophylaxis in patients with atrial fibrillation in mexico[J].Am J Cardiovasc Drugs,2016,16(3):171-182.
[5] 包 蕾.阿加曲班联合阿司匹林治疗急性脑梗死疗效及对患者血管内皮功能的影响[J].陕西医学杂志,2021,50(5):603-605,625.
[6] Walter B,Sylvia T,Alan E,et al.Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage[J].Thrombosis Res,2020,185(3):109-118.
[7] Kiouptsi K,Reinhardt C.Protein disulfide-isomerase-a trigger of tissue factor-dependent thrombosis[J].Clin Hemorheol Microcirc,2016,64(3):279-286.
[8] Langer F,Ruf W.Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation[J].Thromb Haemost,2014,111(4):590-597.
[9] Chinetti GG,Copin C,Derudas B,et al.Peroxisome proliferator-activated receptor γ induces the expression of tissue factor pathway inhibitor-1(TFPI-1)in human macrophages[J].PPAR Res,2016(2016):2756781.
[10] 赵开华.三七“生打熟补”物质基础及药理作用研究进展[J].中医临床研究,2018,10(13):19-20.
[11] 张 洁.中药三七的药理作用及研究进展[J].中国卫生产业,2017,14(28):40-41.
[12] 王 哲,王 娅,刘艳飞,等.中药治疗心房颤动的系统评价再评价[J].中国循证医学杂志,2020,20(2):199-206.
[13] 师 帅,张菀桐,陈 雯,等.芪珀生脉颗粒对心房纤颤大鼠模型血浆cAMP、cGMP、cAMP/cGMP影响的研究[J].北京中医药,2016,35(8):734-737.
[14] 刘泽霖.血栓形成机制中的相关进展[J].血栓与止血学,2019,25(1):1-3.
[15] 董伟伟,吴彩兰.甲状腺功能亢进症与血栓形成相关性研究进展[J].陕西医学杂志,2021,50(2):251-253,257.
[16] Sambola A,Francisco J,Garcia BB,et al.Tissue factor pathway inhibitor is an early biomarker of myocardial injury in patients with ST-segment elevation acute myocardial infarction[J].Int J Cardiol,2014,172(1):279-281.
[17] Cisowska ME,Mazij MP,Kotschy MH,et al.Plasma concentrations of tissue factor and its and inhibitor in chronic thromboembolic pulmonary hypertension:A step closer to explanation of the disease aetiology[J].Kardiol Pol,2016,74(11):1332-1338.
[18] 文颖娟.基于国医大师雷忠义痰瘀互结理论的临床思维启示[J].陕西中医,2020,41(7):948-950,998.
[19] 张 敏,龚 慧,周冬初.血三七活性成分和药理作用研究进展[J].中国医院用药评价与分析,2019,19(12):1528-1531,1536.
[20] 舒 斌,林 娜,丁亚军.注射用三七素对动物实验性损伤的止血作用[J].云南中医学院学报,2018,41(3):12-16.
[21] 金硕果,尹海燕,孙鸿辉,等.三七对轻型缺血性脑卒中患者“双抗”治疗后出血事件影响的研究[J].陕西中医,2019,40(3):287-289.
[22] 周红辉,吴玉婷,赵 恒,等.三七皂苷对SD大鼠血小板聚集及人凝血酶时间影响的研究[J].实用中西医结合临床,2019,19(10):1-2,9.

相似文献/References:

[1]韩乔木,宫丽鸿,吴启华,等.化痰祛瘀方对心房颤动大鼠血管细胞黏附分子-1及血管性血友病因子的影响[J].陕西中医,2022,(9):1180.[doi:DOI:10.3969/j.issn.1000-7369.2022.09.006]
　HAN Qiaomu,GONG Lihong,WU Qihua,et al.Effects of Huatan Quyu formula on rats with atrial fibrillation in serum VCAM-1 and vWF[J].,2022,(11):1180.[doi:DOI:10.3969/j.issn.1000-7369.2022.09.006]

备注/Memo

备注/Memo:
基金项目:陕西省中医药管理局课题(JCMS010); 西安市科技计划项目[20YXYJ0012(13)]
更新日期/Last Update: 2021-11-10